545 related articles for article (PubMed ID: 21377916)
21. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.
Hirota K; Hashimoto M; Yoshitomi H; Tanaka S; Nomura T; Yamaguchi T; Iwakura Y; Sakaguchi N; Sakaguchi S
J Exp Med; 2007 Jan; 204(1):41-7. PubMed ID: 17227914
[TBL] [Abstract][Full Text] [Related]
22. The roles of IL-17A in inflammatory immune responses and host defense against pathogens.
Iwakura Y; Nakae S; Saijo S; Ishigame H
Immunol Rev; 2008 Dec; 226():57-79. PubMed ID: 19161416
[TBL] [Abstract][Full Text] [Related]
23. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?
Lubberts E
Cytokine; 2008 Feb; 41(2):84-91. PubMed ID: 18039580
[TBL] [Abstract][Full Text] [Related]
24. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo.
Gyülvészi G; Haak S; Becher B
Eur J Immunol; 2009 Jul; 39(7):1864-9. PubMed ID: 19544494
[TBL] [Abstract][Full Text] [Related]
25. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
27. Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen.
Noguchi D; Wakita D; Ohkuri T; Tajima M; Chamoto K; Kitamura H; Nishimura T
Immunol Lett; 2011 May; 136(2):146-55. PubMed ID: 21256159
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
[TBL] [Abstract][Full Text] [Related]
29. Regulation of gut inflammation and th17 cell response by interleukin-21.
Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
[TBL] [Abstract][Full Text] [Related]
30. Th17 cytokines and their emerging roles in inflammation and autoimmunity.
Fouser LA; Wright JF; Dunussi-Joannopoulos K; Collins M
Immunol Rev; 2008 Dec; 226():87-102. PubMed ID: 19161418
[TBL] [Abstract][Full Text] [Related]
31. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
32. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production.
Xie L; Li XK; Funeshima-Fuji N; Kimura H; Matsumoto Y; Isaka Y; Takahara S
Int Immunopharmacol; 2009 May; 9(5):575-81. PubMed ID: 19539560
[TBL] [Abstract][Full Text] [Related]
33. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
34. The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model.
Ferraccioli G; Zizzo G
Discov Med; 2011 May; 11(60):413-24. PubMed ID: 21616040
[TBL] [Abstract][Full Text] [Related]
35. TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection.
Akdis M; Palomares O; van de Veen W; van Splunter M; Akdis CA
J Allergy Clin Immunol; 2012 Jun; 129(6):1438-49; quiz1450-1. PubMed ID: 22657405
[TBL] [Abstract][Full Text] [Related]
36. IL-9 signaling as key driver of chronic inflammation in mucosal immunity.
Neurath MF; Finotto S
Cytokine Growth Factor Rev; 2016 Jun; 29():93-9. PubMed ID: 26976761
[TBL] [Abstract][Full Text] [Related]
37. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
38. Pathological role of IL-6 in the experimental allergic bronchial asthma in mice.
Doganci A; Sauer K; Karwot R; Finotto S
Clin Rev Allergy Immunol; 2005 Jun; 28(3):257-70. PubMed ID: 16129910
[TBL] [Abstract][Full Text] [Related]
39. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis.
Gerlach K; Daniel C; Lehr HA; Nikolaev A; Gerlach T; Atreya R; Rose-John S; Neurath MF; Weigmann B
Cancer Res; 2012 Sep; 72(17):4340-50. PubMed ID: 22738913
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
